Clinical Trials

Professor Liu Yunjian: Interpreting the DS8201-A-U105 Study and Discussing the Future of ADC Combined Immunotherapy

by
Professor Liu Yunjian: Interpreting the DS8201-A-U105 Study and Discussing the Future of ADC Combined Immunotherapy

Introduction The DS8201-A-U105 study reveals the latest advancements in ADC combined immunotherapy. What insights can we draw from it? The annual European Society for Medical Oncology Breast Cancer (ESMO BC) conference was officially held from May 3-5, 2022, reporting a series of significant advancements in the field of breast cancer. ADCs have become star drugs … Read more

The Predicament of Established ADC Biotech

by
The Predicament of Established ADC Biotech

Not all long-established ADC Biotechs can achieve a successful exit like Seagen (Seattle Genetics). Today, Mersana Therapeutics, a 23-year-old veteran biotech, has reached its most desperate moment. With a cumulative deficit of $900 million and only $134.6 million left in cash, its two core pipeline products are still in Phase I clinical trials. To sustain … Read more

ADC on the Edge: The Struggles of Chinese Pharmaceutical Companies Amid Technical Shortcomings and Capital Withdrawal

by
ADC on the Edge: The Struggles of Chinese Pharmaceutical Companies Amid Technical Shortcomings and Capital Withdrawal

This March, the American biotechnology company Elevation Oncology announced the termination of the development pipeline for EO-3021 (Claudin 18.2 ADC) licensed from Shiyao Group, redirecting resources to EO-1022 (HER-3 ADC).In July 2022, Shiyao Group licensed EO-3021 to Elevation, which paid a $27 million upfront fee along with potential milestone payments of up to $1.148 billion … Read more

Rapid Advances in ADC: A Cold Reflection Amidst Global Competition

by
Rapid Advances in ADC: A Cold Reflection Amidst Global Competition

01 Domestic B7H3 ADC: From Clinical Data to Market Ambitions In 2024, the global ADC landscape is set to reach a turning point amidst the celebration of DS-8201 breaking the $10 billion expectation, with the B7H3 target emerging as a dark horse and becoming the next storm center. Taking domestic products as an example, although … Read more

The Fragility of ADCs: A Critical Analysis of China’s Biopharmaceutical Landscape

by
The Fragility of ADCs: A Critical Analysis of China's Biopharmaceutical Landscape

If you were to ask what the most fruitful achievement of China’s pharmaceutical industry has been over the past two years, ADC drugs would undoubtedly be considered “top-tier”. From the $2.6 billion licensing deal of Rongchang Biologics’ Vadastuximab in 2021, to the over $10 billion ADC collaboration between Kelun-Biotech and Merck in 2022, and then … Read more

50 In Vitro Diagnostic Instruments and 393 In Vitro Diagnostic Reagents Exempt from Clinical Trials

by
50 In Vitro Diagnostic Instruments and 393 In Vitro Diagnostic Reagents Exempt from Clinical Trials

Click the above “CAIVD” to follow us In 2018, the National Medical Products Administration released the “Catalog of Medical Devices Exempt from Clinical Trials” (hereinafter referred to as the new “Exemption Catalog”). The new “Exemption Catalog” includes a total of 1248 medical devices exempt from clinical trials, divided into two parts: “Medical Device Products” and … Read more

Can Vitamin C Prevent and Treat COVID-19? Insights from Pharmacists

by
Can Vitamin C Prevent and Treat COVID-19? Insights from Pharmacists

According to a report from Health Times on February 14, the team led by Professor Peng Zhiyong at Zhongnan Hospital of Wuhan University is conducting clinical trials on high-dose Vitamin C treatment for COVID-19, suggesting that Vitamin C may be used for treating COVID-19. Professor Peng Zhiyong explained that the dosage of Vitamin C used … Read more

Potential Efficacy of High-Dose Vitamin C in Terminal Cancer Treatment

by
Potential Efficacy of High-Dose Vitamin C in Terminal Cancer Treatment

Medical researchers are not only continuously developing new anti-tumor drugs but are also trying to find new uses for old drugs, hoping to alleviate the suffering caused by cancer and extend survival. High-dose vitamin C treatment for cancer is one of these methods, which is still under research. Many people may wonder how vitamin C, … Read more

Clinical Practice and Research Progress of Artificial Liver Treatment

by
Clinical Practice and Research Progress of Artificial Liver Treatment

Hepatic failure is a common critical condition caused by severe liver dysfunction, particularly acute (subacute) liver failure and subacute liver failure, which progress rapidly and have a high mortality rate. The basic principle of the artificial liver support system is to temporarily replace part of the liver’s function through extracorporeal mechanical, physicochemical, and biological devices, … Read more

Lessons Learned in ADC Clinical Development

by
Lessons Learned in ADC Clinical Development

Introduction Antibody-drug conjugates (ADC) are formed by linking monoclonal antibodies targeting specific antigens with small molecule cytotoxic drugs through linkers, combining the powerful killing effect of traditional small molecule chemotherapy with the tumor targeting ability of antibody drugs. Since ADCs first entered clinical trials in the mid-1990s, they have developed into a very successful oncology … Read more